IPP Bureau
Government constitutes National Dental Commission to transform dental education
By IPP Bureau - March 23, 2026
The government has appointed Dr. Sanjay Tewari as Chairperson, National Dental Commission and Dr. Mousumi Goswami, Part-Time Member, National Dental Commission
Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026
By IPP Bureau - March 23, 2026
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
Avid Organics launches first commercial-scale bio-based glycolic acid at in-cosmetics Global
By IPP Bureau - March 23, 2026
India’s largest glycolic acid manufacturer will unveil AviGa Bio HP70 on April 14, 2026
LGM Pharma commits $15M to US facilities in major CDMO expansion
By IPP Bureau - March 23, 2026
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial
By IPP Bureau - March 23, 2026
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
$7 million grant to UW Institute for protein design to fuel next-gen enzyme breakthroughs
By IPP Bureau - March 23, 2026
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051
By IPP Bureau - March 23, 2026
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
Aesthetic Revolution: Global study reveals patients demand personalised, long-term beauty plans
By IPP Bureau - March 21, 2026
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
Sakura Finetek and Hamamatsu forge alliance to transform digital pathology workflow
By IPP Bureau - March 21, 2026
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes
By IPP Bureau - March 21, 2026
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare
By IPP Bureau - March 21, 2026
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
Pfizer warns shareholders against Tutanota’s mini-tender offer
By IPP Bureau - March 21, 2026
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU
By IPP Bureau - March 21, 2026
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer
By IPP Bureau - March 21, 2026
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
